{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-26-000033","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.890687+00:00","generated_at":"2026-05-16T04:43:32.434727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed","bullets":["Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.","REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.","Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.","Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.","Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-26-000033","json":"https://secwatch.observer/filing/0000879407-26-000033.json","markdown":"https://secwatch.observer/filing/0000879407-26-000033.md","text":"https://secwatch.observer/filing/0000879407-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/0000879407-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/arwr-20260205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:43:32.434727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}